ArticleArthritis research & therapy2026
Artemisinin increases susceptibility to ferroptosis of fibroblast-like synoviocytes in rheumatoid arthritis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveRheumatoid arthritis (RA) is a chronic inflammatory disease characterized by extensive synovial hyperplasia. Artemisinin (ART), a compound extracted from the traditional Chinese herb artemisia annua, has been proven to have anti-malarial and anti-cancer effects. Recently, the ability of artemisinin to induce ferroptosis has shown inhibitory effects on tumor cell proliferation. This study intends to examine whether artemisinin can inhibit the proliferation of RA synovial cells by sensitizing them to ferroptosis.
methodThe effect of artemisinin on fibroblast-like synoviocytes (FLSs) were detected by methods such as CCK8, Western Blot, and immunofluorescence. A collagen-induced mouse model of rheumatoid arthritis was established by injecting collagen and Freund's adjuvant, and the mice were treated with artemisinin following model induction. Synovium was extracted, and imaging examinations along with immunostaining were used to identify the progression of ferroptosis.
resultsThe results revealed that ART increases the susceptibility of FLSs to ferroptosis inducers. The expression of ferroptosis-related proteins, such as glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), was decreased compared with controls. Meanwhile, intracellular lipid peroxides continued to accumulate after artemisinin treatment. Additionally, ferroptosis inhibitors such as deferoxamine (DFO) and Ferrostatin (Fer-1) can inhibit artemisinin-sensitized ferroptosis. The artemisinin-sensitized ferroptosis was related to the increase of P53. In vivo experiments on collagen-induced arthritis mouse models further confirmed that artemisinin relieved joint injury by sensitizing synovial ferroptosis, which was abolished by ferroptosis inhibitors.
conclusionArtemisinin can increase the sensitivity of FLSs to ferroptosis and inhibit the proliferation of synovial cells in rheumatoid arthritis. The P53-SLC7A11 pathway play the important role in this process.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.